Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma

Roger J. Packer, Amar Gajjar, Gilbert Vezina, Lucy Rorke-Adams, Peter C. Burger, Patricia L. Robertson, Lisa Bayer, Deborah LaFond, Bernadine R. Donahue, MaryAnne H. Marymont, Karin Muraszko, James Langston, Richard Sposto

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies. Methods: Four hundred twenty-one patients between 3 years and 21 years of age with nondisseminated medulloblastoma (MB) were prospectively randomly assigned to treatment with 23.4 Gy of CSRT, 55.8 Gy of posterior fossa RT, plus one of two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and vincristine; or cyclophosphamide, cisplatin, and vincristine. Results: Forty-two of 421 patients enrolled were excluded from analysis. Sixty-six of the remaining 379 patients had incompletely assessable postoperative studies. Five-year EFS and survival for the cohort of 379 patients was 81 % ± 2.1 % and 86% ± 9%, respectively (median follow-up over 5 years). EFS was unaffected by sex, race, age, treatment regimen, brainstem involvement, or excessive anaplasia. EFS was detrimentally affected by neuroradiographic unassessability. Patients with areas of frank dissemination had a 5-year EFS of 36% ± 15%. Sixty-seven percent of progressions had some component of dissemination. There were seven second malignancies. Infections occurred more frequently on the cyclophosphamide arm and electrolyte abnormalities were more common on the CCNU regimen. Conclusion: This study discloses an encouraging EFS rate for children with nondisseminated MB treated with reduced-dose craniospinal radiation and chemotherapy. Additional, careful, step-wise reductions in CSRT in adequately staged patients may be possible.

Original languageEnglish (US)
Pages (from-to)4202-4208
Number of pages7
JournalJournal of Clinical Oncology
Volume24
Issue number25
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Medulloblastoma
Adjuvant Chemotherapy
Disease-Free Survival
Radiotherapy
Lomustine
Vincristine
Cyclophosphamide
Cisplatin
Anaplasia
Drug Therapy
Survival
Second Primary Neoplasms
Electrolytes
Brain Stem
Survival Rate
Radiation
Therapeutics
Infection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Packer, R. J., Gajjar, A., Vezina, G., Rorke-Adams, L., Burger, P. C., Robertson, P. L., ... Sposto, R. (2006). Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. Journal of Clinical Oncology, 24(25), 4202-4208. https://doi.org/10.1200/JCO.2006.06.4980

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. / Packer, Roger J.; Gajjar, Amar; Vezina, Gilbert; Rorke-Adams, Lucy; Burger, Peter C.; Robertson, Patricia L.; Bayer, Lisa; LaFond, Deborah; Donahue, Bernadine R.; Marymont, MaryAnne H.; Muraszko, Karin; Langston, James; Sposto, Richard.

In: Journal of Clinical Oncology, Vol. 24, No. 25, 01.09.2006, p. 4202-4208.

Research output: Contribution to journalArticle

Packer, RJ, Gajjar, A, Vezina, G, Rorke-Adams, L, Burger, PC, Robertson, PL, Bayer, L, LaFond, D, Donahue, BR, Marymont, MH, Muraszko, K, Langston, J & Sposto, R 2006, 'Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma', Journal of Clinical Oncology, vol. 24, no. 25, pp. 4202-4208. https://doi.org/10.1200/JCO.2006.06.4980
Packer, Roger J. ; Gajjar, Amar ; Vezina, Gilbert ; Rorke-Adams, Lucy ; Burger, Peter C. ; Robertson, Patricia L. ; Bayer, Lisa ; LaFond, Deborah ; Donahue, Bernadine R. ; Marymont, MaryAnne H. ; Muraszko, Karin ; Langston, James ; Sposto, Richard. / Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 25. pp. 4202-4208.
@article{7cf1fc04e66248468f088eccefb860f0,
title = "Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma",
abstract = "Purpose: To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies. Methods: Four hundred twenty-one patients between 3 years and 21 years of age with nondisseminated medulloblastoma (MB) were prospectively randomly assigned to treatment with 23.4 Gy of CSRT, 55.8 Gy of posterior fossa RT, plus one of two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and vincristine; or cyclophosphamide, cisplatin, and vincristine. Results: Forty-two of 421 patients enrolled were excluded from analysis. Sixty-six of the remaining 379 patients had incompletely assessable postoperative studies. Five-year EFS and survival for the cohort of 379 patients was 81 {\%} ± 2.1 {\%} and 86{\%} ± 9{\%}, respectively (median follow-up over 5 years). EFS was unaffected by sex, race, age, treatment regimen, brainstem involvement, or excessive anaplasia. EFS was detrimentally affected by neuroradiographic unassessability. Patients with areas of frank dissemination had a 5-year EFS of 36{\%} ± 15{\%}. Sixty-seven percent of progressions had some component of dissemination. There were seven second malignancies. Infections occurred more frequently on the cyclophosphamide arm and electrolyte abnormalities were more common on the CCNU regimen. Conclusion: This study discloses an encouraging EFS rate for children with nondisseminated MB treated with reduced-dose craniospinal radiation and chemotherapy. Additional, careful, step-wise reductions in CSRT in adequately staged patients may be possible.",
author = "Packer, {Roger J.} and Amar Gajjar and Gilbert Vezina and Lucy Rorke-Adams and Burger, {Peter C.} and Robertson, {Patricia L.} and Lisa Bayer and Deborah LaFond and Donahue, {Bernadine R.} and Marymont, {MaryAnne H.} and Karin Muraszko and James Langston and Richard Sposto",
year = "2006",
month = "9",
day = "1",
doi = "10.1200/JCO.2006.06.4980",
language = "English (US)",
volume = "24",
pages = "4202--4208",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma

AU - Packer, Roger J.

AU - Gajjar, Amar

AU - Vezina, Gilbert

AU - Rorke-Adams, Lucy

AU - Burger, Peter C.

AU - Robertson, Patricia L.

AU - Bayer, Lisa

AU - LaFond, Deborah

AU - Donahue, Bernadine R.

AU - Marymont, MaryAnne H.

AU - Muraszko, Karin

AU - Langston, James

AU - Sposto, Richard

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Purpose: To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies. Methods: Four hundred twenty-one patients between 3 years and 21 years of age with nondisseminated medulloblastoma (MB) were prospectively randomly assigned to treatment with 23.4 Gy of CSRT, 55.8 Gy of posterior fossa RT, plus one of two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and vincristine; or cyclophosphamide, cisplatin, and vincristine. Results: Forty-two of 421 patients enrolled were excluded from analysis. Sixty-six of the remaining 379 patients had incompletely assessable postoperative studies. Five-year EFS and survival for the cohort of 379 patients was 81 % ± 2.1 % and 86% ± 9%, respectively (median follow-up over 5 years). EFS was unaffected by sex, race, age, treatment regimen, brainstem involvement, or excessive anaplasia. EFS was detrimentally affected by neuroradiographic unassessability. Patients with areas of frank dissemination had a 5-year EFS of 36% ± 15%. Sixty-seven percent of progressions had some component of dissemination. There were seven second malignancies. Infections occurred more frequently on the cyclophosphamide arm and electrolyte abnormalities were more common on the CCNU regimen. Conclusion: This study discloses an encouraging EFS rate for children with nondisseminated MB treated with reduced-dose craniospinal radiation and chemotherapy. Additional, careful, step-wise reductions in CSRT in adequately staged patients may be possible.

AB - Purpose: To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies. Methods: Four hundred twenty-one patients between 3 years and 21 years of age with nondisseminated medulloblastoma (MB) were prospectively randomly assigned to treatment with 23.4 Gy of CSRT, 55.8 Gy of posterior fossa RT, plus one of two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and vincristine; or cyclophosphamide, cisplatin, and vincristine. Results: Forty-two of 421 patients enrolled were excluded from analysis. Sixty-six of the remaining 379 patients had incompletely assessable postoperative studies. Five-year EFS and survival for the cohort of 379 patients was 81 % ± 2.1 % and 86% ± 9%, respectively (median follow-up over 5 years). EFS was unaffected by sex, race, age, treatment regimen, brainstem involvement, or excessive anaplasia. EFS was detrimentally affected by neuroradiographic unassessability. Patients with areas of frank dissemination had a 5-year EFS of 36% ± 15%. Sixty-seven percent of progressions had some component of dissemination. There were seven second malignancies. Infections occurred more frequently on the cyclophosphamide arm and electrolyte abnormalities were more common on the CCNU regimen. Conclusion: This study discloses an encouraging EFS rate for children with nondisseminated MB treated with reduced-dose craniospinal radiation and chemotherapy. Additional, careful, step-wise reductions in CSRT in adequately staged patients may be possible.

UR - http://www.scopus.com/inward/record.url?scp=33748660920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748660920&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.06.4980

DO - 10.1200/JCO.2006.06.4980

M3 - Article

VL - 24

SP - 4202

EP - 4208

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -